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average 6.9 injections, with a final VA gain of 8.3 ± 15.0 let-
ters (p = 0.05). BRVO eyes had on average 5.9 injections, 
with a final VA gain of 1.6 ± 21.0 letters (p > 0.05). The FAZ 
area remained stable in both groups (p > 0.05). Baseline 
BCVA and disruption of the retinal pigment epithelium 
(RPE) were predictors of final BCVA (p = 0.001 and 0.011, re-
spectively).  Conclusion: Although functional outcomes 
were inferior to those reported in clinical trials, ranibizumab 
was satisfactory in the long-term treatment of macular ede-
ma secondary to RVO and was not associated with increased 
macular ischemia. Final BCVA depends on baseline BCVA 
and RPE integrity.  © 2015 S. Karger AG, Basel 
 Introduction 
 Retinal vein occlusion (RVO) has different manifesta-
tions and may present as central RVO (CRVO), or hemi-
central or branch RVO (BRVO). It is the second most 
common cause of reduced vision due to retinal vascular 
disease after diabetic retinopathy  [1–5] . 
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 Abstract 
 Purpose: To evaluate long-term results and predictors of 
efficacy in patients with macular edema due to retinal vein 
occlusion (RVO) treated with intravitreal ranibizumab in a 
clinical practice setting.  Methods: The clinical records of pa-
tients with a minimum follow-up of 3 years were retrospec-
tively analyzed. Sixteen eyes with branch RVO (BRVO) and 
16 with central RVO (CRVO) were included. All patients per-
formed cross-sectional evaluation with best-corrected vi-
sual acuity (BCVA), spectral domain optical coherence to-
mography and fluorescein angiography. The foveal avas-
cular zone (FAZ) was assessed and microstructural mor-
phology of the retina was characterized.  Results: Follow-
up was 42.9 ± 9.0 and 44.8 ± 8.0 months in the CRVO and 
BRVO groups, respectively. Patients with CRVO received on 
 Received: September 3, 2015 
 Accepted: September 3, 2015 
 Published online: November 6, 2015 
 Rufino Silva, MD, PhD  
 Centro de Responsabilidade Integrado de Oftalmologia 
 Centro Hospitalar e Universitário de Coimbra 
 Praceta Mota Pinto, PT–3049 Coimbra (Portugal) 
 E-Mail rufino.silva   @   oftalmologia.co.pt 


























   
   
   
   
   
   




















 Ranibizumab for RVO in Clinical Practice  Ophthalmic Res 2016;55:10–18 
DOI: 10.1159/000440848
11
 Increased production of vascular endothelial growth 
factor (VEGF) occurs early in the disease process and is a 
major contributor to macular edema  [6–8] . Thus, block-
age of VEGF with anti-VEGF agents, such as ranibizumab 
(Lucentis ® ; Novartis, Basel, Switzerland), raised hopes to 
reduce macular edema and improve vision. Two pivotal 
trials finally established the role of anti-VEGF therapy in 
RVO: the Treatment of Macular Edema following Branch 
Retinal Vein Occlusion: Evaluation of Efficacy and Safety 
(BRAVO)  [9] and the Treatment of Macular Edema fol-
lowing Central Retinal Vein Occlusion: Evaluation of
Efficacy and Safety (CRUISE) trials  [10] . Overall, the 
12-month results showed that the visual gain was good 
and could be maintained. Moreover, early treatment with 
anti-VEGF led to a greater functional improvement than 
delayed therapy  [11, 12] . The long-term outcomes in 
BRVO patients were excellent, although half still required 
occasional injections after 4 years. Most CRVO patients, 
however, still require frequent injections within a 4-year 
follow-up and had a more guarded prognosis  [13] . These 
good results have been confirmed in many smaller studies 
 [14–16] . An important aspect of anti-VEGF treatments, 
however, is the drug delivery protocol used in real-life 
clinical practice, which can be significantly different from 
that used in well-controlled clinical trials. Few reports ex-
ist on this matter in RVO, and none of them evaluated the 
associated long-term outcomes  [17, 18] . Also, some de-
bate has been raised about the role of anti-VEGF agents in 
promoting retinal nonperfusion (RNP) or, on the con-
trary, in reducing retinal ischemia by promoting retinal 
reperfusion  [1, 19–21] . The impact of anti-VEGF agents 
in the choroid is also still poorly understood  [22, 23] . 
 The purpose of this study is to evaluate the long-term 
results of intravitreal ranibizumab (IVR) in the treatment 
of macular edema due to RVO in a clinical practice setting 
and to identify morphological factors related to function-
al outcome with multimodal retinal imaging.
 Materials and Methods 
 A retrospective and cross-sectional study was conducted at the 
Ophthalmology Department of the Centro Hospitalar e Universi-
tário de Coimbra and the Association for Innovation and Biomed-
ical Research on Light and Image (AIBILI). Signed informed con-
sent was obtained from all subjects, and the study was conducted 
in accordance with the tenets of the Declaration of Helsinki and 
after institutional review board approval. 
 The medical records of consecutive patients with RVO fol-
lowed in our Department were examined. Eyes with a history of 
RVO treated with IVR and a minimum follow-up of 3 years were 
included if there was no history of other vitreoretinal disease, uve-
itis, dense cataract or other pathologies that could compromise 
visual acuity (VA). Patients with a history of previous vitrectomy 
and/or a scleral buckling procedure were also excluded. All pa-
tients started treatment with 0.5 mg ranibizumab (Lucentis), using 
a pro renata (PRN) regimen without a loading dose, if best-correct-
ed VA (BCVA) was inferior to 20/32 due to macular edema, which 
was confirmed with optical coherence tomography (OCT). During 
follow-up, retreatment was performed if there was BCVA loss
superior to 5 Early Treatment of Diabetic Retinopathy Study
(ETDRS) letters (L), and/or in the presence of intraretinal or sub-
retinal fluid in OCT.
 Patients’ medical records were reviewed for data, including
demographics, follow-up time, BCVA evolution (with ETDRS 
charts), central macular thickness (CMT) evolution acquired by 
automated fast macular thickness map in spectral domain OCT 
(SD-OCT), number of IVR injections, other treatments performed 
previously for macular edema, development of neovascular disease 
and treatment with panretinal photocoagulation, other ocular co-
morbidities and intraocular surgery, and systemic or adverse ef-
fects related with IVR treatment.
 A final cross-sectional evaluation was also performed in all pa-
tients including: BCVA (ETDRS charts), slit lamp examination 
and dilated fundus stereoscopic examination with +90- and 
+60-diopter lenses, color fundus photography, fluorescein angiog-
raphy (FA) and SD-OCT with Spectralis ® OCT (Heidelberg Engi-
neering, Heidelberg, Germany) in both retinal and choroidal mode 
[enhanced depth imaging OCT (EDI-OCT)].
 The foveal avascular zone (FAZ) area was measured in the first 
available angiogram and in the angiogram performed in the final 
cross-sectional visit. For this purpose, 2 independent observers 
(C.F. and J.P.M.) used RetmarkerAMD ® software (Critical Health 
ba
 Fig. 1. Print screens of real-time grading 
using RetmarkerAMD ® . After manually 
marking the optic disk diameter and the 
center of the fovea, the software generates 
a reference grid ( a ). The FAZ area is then 
manually delineated ( b ), and the respective 
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SA, Coimbra, Portugal) to manually delineate the FAZ and the 
area was automatically calculated by the software. The software 
divides the posterior pole in 10 subfields with a circular grid cen-
tered in the macula and calibrated through the edges of the optic 
disk, identical to the ETDRS-style macular grid (which comprises 
1-, 3- and 6-mm concentric circles). The central subfield overlaps 
with the central macula ( fig. 1 )  [24] . Other areas of RNP were also 
qualitatively analyzed for classification into ischemic/nonischemic 
subtypes in the final visit. It was considered as ischemic if the RNP 
area was greater than 10 disk areas in eyes with CRVO and 5 disk 
areas in eyes with BRVO.
 Microstructural qualitative analysis of the retina using SD-OCT 
was performed before baseline treatment and at the final cross-sec-
tional evaluation by the same 2 authors (C.F. and J.P.M.). The hyper-
reflective lines corresponding to the external limiting membrane 
(ELM), inner (IS) and outer segment (OS) junction and retinal pig-
ment epithelium (RPE) were also classified as being disrupted or 
intact. Any disagreement was resolved by the senior author (R.S.).
 EDI-OCT with Spectralis OCT (Heidelberg Engineering) was 
performed to measure the choroidal thickness (CT). The method 
of obtaining EDI-OCT images and CT measurements has been re-
ported previously  [25, 26] . Both the horizontal and vertical sections 
passing through the center of the fovea were used for the CT mea-
surements, which were obtained manually under the fovea using 
the scale supplied with the software, and at 1,000- and 3,000-μm 
distance to the fovea in the nasal, temporal, superior and inferior 
directions. Each image was measured by 2 independent observers 
(C.F. and J.P.M.) and the average of the 2 was considered for anal-
ysis. Data with discrepancies of 15% were reanalyzed by the senior 
author (R.S.). The average of 10 readings taken in each eye was con-
sidered the macular CT. The average of the 2 subfoveal readings 
(vertical and horizontal) was considered the subfoveal CT.
 Statistical analysis was performed using Stata software (version 
12.1; StataCorp LP). Univariate analysis was performed on a basis 
of variable selection for the multivariate analysis, using Mann-
Whitney U and paired Wilcoxon tests, and Spearman’s correlation 
coefficient. A multiple regression model was used to identify inde-
pendent prognostic factors for final BCVA, including the variables 
selected in the univariate analysis.
 Results 
 Patient Demographic Data 
 Thirty-two eyes of 32 patients (15 females and 17 males) 
were included. Sixteen eyes were included in the CRVO 
group (15 eyes with CRVO diagnosis and 1 eye with hemi-
central vein occlusion) and 16 eyes in BRVO group. In the 
latter, 14 eyes had major BRVO and 2 eyes had macular 
BRVO. Age, gender, follow-up time and systemic risk fac-
tors for RVO are presented by group in  table 1 . Five eyes 
(31%) in the CRVO group and 2 eyes (13%) in the BRVO 
group were pseudophakic. Four eyes (25%) in the CRVO 
group and 2 (13%) eyes in the BRVO group had a previous 
diagnosis of glaucoma, all of them controlled with topical 
medication. Considering the previous treatments for mac-
ular edema: 3 eyes in the CRVO group had already received 
intravitreal triamcinolone and/or bevacizumab (2 injec-
tions maximum), and 4 eyes in the BRVO group had been 
treated previously with macular grid laser and/or intravit-
real triamcinolone (1 injection maximum).
 Evolution and Cross-Sectional Evaluation of BCVA 
and CMT 
 CRVO Group. Gain in BCVA was significant only at 
the 6-month evaluation (p = 0.018). The final mean 
BCVA in the cross-sectional evaluation was 55.4 ± 23.6 L, 
which represents a final mean gain of 8.3 ± 15.0 L (p = 
0.05, borderline significant;  fig. 2 ;  table 2 ).
 Table 1.  Patient demographics by group
CRVO BRVO
Age at treatment initiation, years 63.9 ± 14.3 68.8 ± 10.5
Follow-up since IVR treatment,
months 42.9 ± 9.0 44.8 ± 8.0
Time between diagnosis and
1st IVR treatment, months 5.4 ± 5.4 8.0 ± 10.7
Gender, males/females 12/4 5/11
Systemic risk factors, n (%)
Diabetes mellitus type 2 1 (6) 3 (19)
High blood pressure 8 (50) 9 (56)
Dyslipidemia 6 (38) 7 (44)










































 Fig. 2. Evolution of BCVA and CMT in the CRVO group during 
follow-up and in the cross-sectional (CS) evaluation. M = Months. 
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 BRVO Group. Gain in BCVA was significant at the 6- 
and 12-month follow-up visits (p = 0.023 and 0.044, re-
spectively). The final mean BCVA in the cross-sectional 
evaluation was 53.3 ± 24.8 L, corresponding to a final 
mean gain of 1.6 ± 21.0 L (p > 0.05;  fig. 3 ;  table 2 ). The 
percentage of eyes that maintained, gained or lost VA is 
presented in  table 3 for both groups. The CMT was sig-
nificantly inferior at all evaluation points compared to 
baseline in both the CRVO and the BRVO group (p < 
0.05;  fig. 2 ,  3 ;  table 2 ).
 Table 2.  Evolution of BCVA and CMT in the CRVO and BRVO groups during follow-up and in the cross-sectional (CS) evaluation
CRVO  BRVO
BCVA, L p value CMT, μm p value BC VA, L p value CMT, μm p value
Initial visit 47.1 ± 26.0 – 666.7 ± 221.4 – 51.8 ± 24.1 – 555.9 ± 225.9 –
6 months 55.3 ± 19.2 0.018 418.6 ± 183.5 0.001 65.1 ± 20.6 0.023 349.9 ± 150.0 0.005
12 months 53.8 ± 21.4 0.087 387.2 ± 175.5 0.002 63.3 ± 19.5 0.044 376.4 ± 136.2 0.013
24 months 54.5 ± 21.8 0.163 385.8 ± 195.5 0.006 57.8 ± 25.0 0.201 351.2 ± 188.3 0.019
36 months 54.3 ± 24.1 0.057 290.1 ± 151.5 0.003 58.1 ± 26.0 0.344 337.6 ± 100.4 0.013
CS visit 55.4 ± 23.6 0.052 303.9 ± 160.3 0.001 53.3 ± 24.8 0.815 337.4 ± 153.5 0.009












































 Fig. 3. Evolution of BCVA and CMT in the BRVO group during 
follow-up and in the cross-sectional (CS) evaluation. M = Months. 




























 Fig. 4. Total number of injections given and by year of follow-up, 
on average, in both groups. M = Months. 
 Table 3.  BCVA in the final cross-sectional evaluation
Group Stabilization (≤5 L) Gain >5 L Gain ≥15 L Gain ≥30 L Loss >5 L Loss ≥15 L Loss ≥30 L
CRVO 38% (n = 6) 6% (n = 1) 31% (n = 5) 13% (n = 2) 6% (n = 1) 6% (n = 1) 0% (n = 0)
BRVO 63% (n = 10) 0% (n = 0) 13% (n = 2) 6% (n = 1) 0% (n = 0) 13% (n = 2) 6% (n = 1)
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 Number of Injections and Complications 
 The average number of injections performed during 
follow-up is presented in  figure 4 . In the CRVO group, 
75% (n = 12) of the eyes required IVR injections after the 
1st year of treatment, and 44% (n = 7) required treatment 
after 2 years of follow-up. In the BRVO group, 50% (n = 
8) of the eyes required IVR injections after the 1st year, 
and 31% (n = 5) after 2 years of follow-up. The mean time 
without treatment since the last injection was 21.6 ± 14.5 
months in the CRVO group and 24.5 ± 17.6 months in 
the BRVO group. 
 In the CRVO group, one eye presented with rubeosis 
and vitreous hemorrhage and another presented with ret-
inal neovascularization during follow-up. Both were suc-
cessfully treated with IVR and panretinal photocoagula-
tion, and had a final VA loss of 5 L and a gain of 31 L, 
respectively. In the BRVO group, 4 eyes developed retinal 
neovascularization and were treated with scatter photo-
coagulation. The final VA of these eyes ranged from 5 to 
60 L (median = 30.5 L), and VA changed between a loss 
of 45 L and a gain of 25 L (median = –12 L).
 No cases of retinal tears, detachment or infections 
were observed in both groups, and there were no report-
ed systemic events.
 OCT and FA 
 Table 4 presents the most common retinal morpho-
logical changes found in OCT when starting treatment 
and in the final visit, and subfoveal and macular CT as 
well as FAZ area measurements performed in both 
groups. There was a statistically significant difference be-
tween both groups for subfoveal CT (p = 0.024) but not 
for age (p > 0.05). The first angiogram was performed on 
average 8.6 ± 10.4 months after the diagnosis of RVO. The 
change between mean baseline and mean final FAZ areas 
was nonsignificant in both groups (p > 0.05). 
 Seven eyes (44%) in the CRVO group and 6 eyes (38%) 
in the BRVO group were classified as ischemic in the final 
visit. Differences between ischemic and nonischemic eyes 
for the final FAZ area and BCVA are presented in  table 5 . 
In the CRVO group, and in spite of the worse final VA, 
ischemic eyes gained 8.6 ± 16.4 L on average (p > 0.05). 
CRVO eyes without ischemia gained on average 8.1 ± 
 Table 4.  Microstructural changes in SD-OCT, CT and FAZ area at initial and final visits in both groups
 CRVO BRVO
initia l final initial final
Macular fluid (cystoid macular edema/subretinal fluid), % 100 (n = 15) 31 (n = 5) 100 (n = 14) 69 (n = 11)
Disruption of the ELM, % 93 (n = 14) 88 (n = 14) 43 (n = 6) 69 (n = 11)
Disruption of the IS/OS line, % 100 (n = 15) 88 (n = 14) 86 (n = 12) 69 (n = 11)
Disruption of the RPE, % 60 (n = 9) 25 (n = 4) 43 (n = 6) 38 (n = 6)
Vitreomacular traction, % 7 (n = 1) 6 (n = 1) 21 (n = 3) 6 (n = 1)
Epiretinal membrane, % 20 (n = 3) 75 (n = 12) 43 (n = 6) 63 (n = 10)
Loss of foveal contour due to macular atrophy, % 0 (n = 0) 31 (n = 5) 0 (n = 0) 6 (n = 1)
Macular CT, μm – 254.0 ± 76.3 – 192.6 ± 55.7
Subfoveal CT, μm – 284.2 ± 93.7 – 205.6 ± 66.2
FAZ area, mm2 0.43 ± 0.34 (n = 9) 0.39 ± 0.21 (n = 12) 0.40 ± 0.31 (n = 12) 0.43 ± 0.27 (n = 13)
 % = Rate of eyes; n = number of eyes. One eye in the CRVO group and 2 eyes in the BRVO group had poor baseline OCT quality preventing morpho-
logical analysis.
 Table 5.  Final FAZ area and BCVA in ischemic and nonischemic eyes in both groups (means ± SD)
CRVO  BRVO
ischemic nonischemic p value ischem ic nonischemic p value
Final FAZ area, mm2 0.48 ± 0.25 0.33 ± 0.11 >0.05 0.47 ± 0.37 0.42 ± 0.23 >0.05
Final BCVA, L 38.6 ± 17.6 68.4 ± 17.2 0.013 37.7 ± 18.4 62.7 ± 22.0 0.020
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12.8 L (p > 0.05). In the BRVO group, ischemic eyes had 
a final mean loss of 7.3 ± 21.5 L (p > 0.05) compared to a 
final mean gain of 6.9 ± 17.4 L in nonischemic eyes (p > 
0.05). Also, as shown in  table 3 , two eyes lost 15 L or more 
and 1 eye lost 30 L or more in the BRVO group. A detailed 
analysis of these patients with severe or very severe VA 
loss showed that the first one who lost 45 L was consid-
ered ischemic in the final visit and had permanent chang-
es in the external layers of the retina in OCT; the second 
lost 15 L because of poor response to treatment with re-
current edema through follow-up in spite of the 11 injec-
tions performed; the third patient lost 19 L and also 
showed poor response to treatment after 5 injections, 
with permanent fluid in OCT until the final visit, and he 
was also considered ischemic in the final visit. 
 Univariate Analysis 
 CRVO Group. Final BCVA correlated with initial 
BCVA (p < 0.001, r = 0.82). Of the baseline and final mor-
phological changes found in OCT, only a disrupted RPE 
status in the final OCT was associated with worse final 
VA (p = 0.018). 
 BRVO Group. Final BCVA correlated with initial 
BCVA (p = 0.020, r = 0.61). Of the morphological chang-
es, baseline disruption of RPE and the final status of ELM 
and IS/OS line negatively affected the final BCVA (p = 
0.008, 0.036 and 0.036, respectively).  Also, a negative cor-
relation was found between final macular and subfoveal 
CT, and final BCVA (p = 0.026, r = –0.57, and p = 0.030, 
r = –0.56). 
 All Eyes Together. RPE disruption at baseline (p = 
0.003) and disruption of RPE, ELM and IS/OS line at the 
final visit (p = 0.006, 0.006 and 0.015, respectively) nega-
tively affected the final VA. Final BCVA was positively 
correlated with initial BCVA (p < 0.001, r = 0.74). 
 As reported, 5 eyes were previously treated with beva-
cizumab and/or triamcinolone, which could be a con-
founding factor. For this reason, we repeated the analysis 
excluding these 5 eyes. Again, only the initial RPE disrup-
tion (p = 0.012), and the final ELM, IS/OS line and RPE 
disruption in OCT were associated with worse final 
BCVA (p = 0.021, 0.021 and 0.041, respectively). The final 
BCVA was again correlated with initial BCVA (p < 0.001, 
r = 0.76). The final CMT was also positively correlated 
with the total number of IVR injections performed dur-
ing follow-up (p = 0.012, r = 0.48).
 Multiple Regression Analysis 
 Regression analysis was performed to identify the pre-
dictive variables for final BCVA considering all eyes to-
gether. For this purpose, we included the OCT morpho-
logical changes found to be significant in univariate anal-
ysis and adjusted for initial BCVA. 
 Being strongly correlated with the final BCVA, initial 
BCVA was found as a positive predictor of the final BCVA 
(p = 0.001), as expected. Among the morphological 
changes in OCT, only the disruption of the RPE before 
starting treatment was predictive of worse final BCVA
(p = 0.011). The remaining morphological variables had 
no predictive value once initial BCVA was considered in 
multivariate analysis.
 The analysis was repeated excluding the 5 eyes previ-
ously treated with bevacizumab and/or triamcinolone. 
The variables with predictive value remained the same: 
initial BCVA (p < 0.001) and baseline status of RPE in 
OCT (p = 0.010).
 Discussion 
 We analyzed the long-term results of intravitreal ra-
nibizumab in the treatment of macular edema due to 
RVO in clinical practice, and we identified predictors of 
functional outcome using multimodal retinal imaging. 
Our results show that baseline disruption of macular RPE 
and initial BCVA are good predictors of functional out-
come, that intravitreal ranibizumab did not prevent ru-
beosis or retinal neovascularization, and that no increase 
in macular ischemia was observed after 3 years or more 
of treatment. 
 VA increased steadily in the first 6 months as expected 
in both groups; however, the observed gain was not as 
good as those reported in the BRAVO and CRUISE trials 
 [9, 10] . This is probably related to the PRN regimen used 
from the beginning instead of fixed monthly injections in 
the first 6 months performed in these trials. In fact, the 
mean number of injections in the 1st year in our study 
was 4.1 in the CRVO group and 3.5 in the BRVO group. 
The protocols implemented in clinical trials are often dif-
ficult to apply in regular clinical settings, and the frequent 
restrictions found in clinical practice may be associated 
with the limited number of injections performed. Recent 
studies analyzed the protocols and frequency of anti-
VEGF treatments for macular edema secondary to RVO 
in clinical practice in the United States. One reported av-
erage bevacizumab injections of 2.5, 3.1 and 3.3 in BRVO, 
and 3.1, 3.1 and 3.5 in CRVO across the years 2008, 2009 
and 2010, respectively. Another reported mean numbers 
of injections of 4.4 ± 2.8 and 4.7 ± 2.9 in patients treated 
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in the 1st year  [17, 18] . This picture is much different 
from the above-mentioned clinical trials and very similar 
to our own experience.
 In the long term, after 43 months of treatment, we 
found a mean gain of 8.3 L in CRVO patients, and 31% 
gained 15 L or more. This was inferior compared to 
CRVO patients from the RETAIN study  [13] , where pa-
tients gained on average 14.0 L from the CRUISE study 
baseline, and 53.1% gained 15 L or more after a mean 
follow-up of 51.4 months. The mean number of injec-
tions per year in the RETAIN study was, however, also 
superior: 4.5 in year 2 and 3.6 in year 3 (3.3 in year 4) 
compared to 1.7 in year 2 and 0.9 in year 3 in our study. 
Although the initial VA gain for CRVO patients was not 
as high, VA remained stable in the long term, with fewer 
injections. 
 In BRVO patients, the RETAIN study  [13] reported an 
improvement of 20.1 L at the end of follow-up, with 61.8% 
of the patients showing an improvement of 15 L or more 
from the BRAVO trial baseline. Our results are different, 
as the gain in VA did not remain constant, but declined, 
with a final mean gain of 1.6 L after 45 months of treat-
ment, and only 13% gained 15 L or more. A more pro-
found analysis revealed, however, that 38% were ischemic 
in the final visit. In fact, 2 eyes lost more than 15 L and 1 
lost more than 30 L, which, considering the small sample 
size of the group, helps to explain the lower final VA. 
Also, excluding ischemic eyes from the analysis, a VA 
gain of 6.9 L would be achieved. More ischemia is associ-
ated with higher levels of VEGF, and in the long term this 
may have a negative impact on VA despite the treatment 
with anti-VEGF. Another important factor is again the 
number of injections performed, which was superior in 
the RETAIN study: 2.6, 2.1 and 2.0 in years 2, 3 and 4, re-
spectively, for BRVO eyes  [13] . Instead, we performed on 
average 1.3 injections in year 2 and 0.6 in year 3. This also 
may have contributed to the progressive loss in VA. 
 CMT decreased steadily and significantly in the first 6 
months, paralleling the most expressive VA gain, in both 
groups. In the CRVO group, CMT continued to decrease 
during follow-up, but VA remained stable. Also, 31% of 
these eyes still had fluid in the final OCT. This is not un-
expected, and Campochiaro et al.  [13] also reported reso-
lution of macular edema in only 43.8% of CRVO cases in 
the long term. In the BRVO group, CMT remained rela-
tively stable, but VA still declined. Sixty-nine percent of 
our BRVO patients still had fluid in the final OCT com-
pared to 50% in RETAIN study. Recurrent and chronic 
edema is thought to lead to loss in VA due to photorecep-
tor damage in the long term  [13] . Probably the morpho-
logical changes at microstructural level from chronic and 
recurrent edema are the reason for this divergence be-
tween CMT and VA. A more aggressive strategy prevent-
ing fluid recurrence could, therefore, lead to improved 
results.
 CT was also assessed in both groups in the final visit, 
and we found that it was superior in the CRVO group 
compared to the BRVO group. Tsuiki et al. [22] have al-
ready reported increased subfoveal CT in CRVO eyes, 
and they also suggested that this is related to vessel dila-
tion and increased permeability by VEGF. Considering 
this assumption, and as CRVO is a global event associ-
ated with higher levels of VEGF, the choroid of these eyes 
could be expected to be thicker compared to BRVO eyes. 
The age difference between the 2 groups, although with-
out significance, may also have contributed to this out-
come, as CT decreases with age  [26] . Tsuiki et al.  [22] also 
found that the subfoveal CT of CRVO eyes decreased
significantly after intravitreal bevacizumab treatment. 
Therefore, inhibition of VEGF by bevacizumab could be 
the cause of this reduction. This can also aid to explain 
the relatively normal values for CT found in the CRVO 
group and the apparently decreased CT readings found 
in the BRVO eyes. 
 Acutely after BRVO or CRVO, there may be mild or 
no RNP (nonischemic RVO), or it may be severe (isch-
emic RVO). Measurements of the area of RNP on FA have 
shown that enlargement of this area is common in both 
BRVO and CRVO  [27, 28] . The mechanism is unknown, 
but concern has been expressed that it may be exacerbat-
ed by VEGF itself  [1, 19] , or on the contrary from its in-
hibition  [20, 21] . For this purpose, we also analyzed the 
changes in the FAZ area in eyes with RVO treated with 
IVR in the long term. These changes were, however, small 
and nonsignificant in both groups. The initial concerns 
of worsening of macular ischemia after prolonged treat-
ment with ranibizumab are, therefore, not supported by 
the findings of our study. 
 Another important finding was that ischemic eyes had 
larger final FAZ areas and worse functional outcome. 
This meets the concept of the influence of higher levels of 
VEGF in the progression of RNP, and the fact that, as 
stated by Sophie et al.  [1] , in patients with RVO infre-
quent ranibizumab injections to control edema may not 
be sufficient to prevent progression of RNP in all cases, 
which in turn may contribute to loss of visual gains in the 
long term. It is also important to notice that in our study, 
treatment with ranibizumab did not prevent the develop-
ment of retinal neovascularization and rubeosis. This was 
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ranibizumab in preventing progression of ischemia and 
subsequent development of neovascular disease must be 
further addressed.
 In the present study, we found that only baseline 
BCVA and microstructural morphological changes in 
OCT were related to the final visual outcome in univari-
ate analysis. Among the morphological changes, only dis-
ruption of the external layers of the retina (ELM, IS/OS 
junction and RPE) reached statistical significance. Re-
gression analysis was also performed to identify the pre-
dictive variables for final BCVA. Only the baseline BCVA 
and the baseline disruption of the RPE were significant 
predictors of visual outcome. Similarly, Coscas et al.  [5] 
also reported that final visual prognosis depends on the 
initial VA and on the presence and ELM integrity, and IS/
OS photoreceptors (IS/OS interface). There was no other 
factor found to have predictive value for functional out-
come, but this may only be due to the small sample size. 
This matter should be further addressed in future studies, 
as optimization of treatment strategies is necessary in 
clinical practice, as supported by our study.
 There are important limitations to this study. Besides 
its retrospective design and small sample, the morpho-
logical measurements of the choroid and FAZ were ob-
tained manually by 2 independent observers, because 
there is no automated software available at present. New 
automated software will reduce the bias involved and the 
time required for measurements. Although the overall 
group was not small, the subgroups were; however, we 
provide further insight into the functional and morpho-
logical evolution of eyes with RVO treated with ranibi-
zumab in the long term in a real-life clinical setting, and 
we explored different factors related to functional out-
come.
 In conclusion, treatment with ranibizumab as needed 
to control macular edema is safe and provides satisfac-
tory long-term results in patients with CRVO and BRVO, 
although functional outcome was not as good as reported 
in clinical trials with higher retreatment rates. Ranibi-
zumab does not seem to contribute to macular ischemia, 
but it did not prevent the development of retinal neovas-
cularization and rubeosis. Final VA depends on the base-
line VA and RPE integrity assessed by means of SD-OCT. 
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